483
Daiichi Sankyo Chemical Pharma Co., Ltd.FDA 483 - Daiichi Sankyo Chemical Pharma Co., Ltd. - November 08, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Daiichi Sankyo Chemical Pharma Co., Ltd.'s Onahama Plant, a drug substance manufacturer, revealed five observations. The findings primarily concerned deficiencies in quality unit approval of procedures, inadequate environmental monitoring, insufficient disinfectant efficacy studies, and scientifically unjustified equipment qualifications. These issues indicate a need for improved quality system controls and validation practices.
Open in Dashboard
ID · 0da57ba4-3f2c-4b5d-9103-cf032e02de4a